AAV-based gene therapies
The company advances these therapies for severe monogenic diseases of the central nervous system.
Source: LinkedIn company description · Retrieved October 13, 2026
Taysha Gene Therapies is a clinical-stage biotechnology company advancing AAV-based gene therapies for severe monogenic diseases of the central nervous system.
Its lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder. The company's management team has experience in gene therapy development and commercialization.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company advances these therapies for severe monogenic diseases of the central nervous system.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 18, 2026, September 19, 2026, September 20, 2026 and September 21, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.